liveBook · Manning

Chapter 13: Multimodal AI Systems for End-to-End Drug Discovery

What you will learn in chapter 13 of Build AI Drug Discovery Pipelines

The introduction frames end-to-end drug discovery as prioritizing target-and-molecule hypotheses for experiments and clarifies the chapter’s three uses of “multimodal.”

After this chapter you will be able to

What it builds on

Section by section

Introduction

The introduction frames end-to-end drug discovery as prioritizing target-and-molecule hypotheses for experiments and clarifies the chapter’s three uses of “multimodal.”

Key terms: target-and-molecule hypotheses, in silico, experimental effort, multimodal, true data fusion, shared representation, single-modality models, end-to-end workflow integration

13.1 From Components to Systems: The Integration Challenge

The section uses rentosertib to show why drug discovery is moving from standalone AI methods toward integrated systems, while cautioning that early clinical signals need confirmation.

Key terms: multimodal platforms, standalone methods, drug discovery pipeline, Rentosertib, INS018_055, TNIK, PandaOmics, Chemistry42, Phase 2a

13.1.1 The Evolution of AI-Driven Drug Discovery

This section traces four waves of computational drug discovery, from isolated predictive tools to integrated platforms that learn from experimental feedback.

Key terms: first wave, second wave, QSAR, docking, deep learning, third wave, generative models, de novo molecular design, variational autoencoders, reinforcement learning

13.1.2 Defining Multimodal AI Systems

Defines multimodal AI systems in drug discovery through four integrated capabilities and distinguishes them from collections of independent computational tools.

Key terms: multimodal dimension, data heterogeneity, multi-model orchestration, data fusion, unified representations, end-to-end dimension, target identification, clinical candidate selection, continuous workflows, feedback loop dimension

13.2 Platform Architecture & Components

Introduces BioNeMo as one example of a modular multimodal drug-discovery platform whose models can be used separately or combined into workflows.

Key terms: modular design, individual components, end-to-end workflows, BioNeMo, open toolchains, open-source or academic

13.2.1 Platform Overview

This section explains how BioNeMo’s model, microservice, and blueprint layers connect specialized protein, small-molecule, genomic, and cellular models into drug discovery workflows.

Key terms: foundation model layer, NIM, blueprint layer, modularity, ESM-2, ProtGPT2, AlphaFold2, ESMFold, predicted structure, pLDDT

13.2.2 Calling a NIM and Reading What Comes Back

This section explains how to interpret hosted Boltz-2 and DiffDock results, using measured ligand series to show what their affinity, confidence, and pose outputs can and cannot establish.

Key terms: mmCIF, complex and per-chain confidence scores, affinity_probability_binary, affinity_pred_value, IC50, DiffDock, rank-1 confidence, potency, rank-1 pose, RMSD

13.2.3 Integration Patterns Across Platforms

This section compares four ways drug discovery platforms integrate AI components, explaining what each pattern does well and where it can fall short.

Key terms: sequential pipeline, PandaOmics, Chemistry42, inClinico, local versus global optimization, parallel ensembles, consensus scoring, in silico evaluation, closed-loop active learning, Design-Make-Test-Learn (DMTL)

13.2.4 Integrating Multimodal Representations

This section explains how drug discovery platforms harmonize diverse biological data and use learned representations to connect evidence across modalities.

Key terms: data harmonization, entity linking, ontology mapping, quality scoring, knowledge graph, batch effect correction, reference compounds, genetic perturbations, biological variation, PandaOmics

13.3 End-to-End Workflows in Practice

13.3.1 Case Study 1: Rentosertib for Idiopathic Pulmonary Fibrosis

The rentosertib case traces an AI-assisted drug program from target selection through molecular design, experimental validation, and early clinical results, showing both discovery gains and remaining limits.

Key terms: PandaOmics, TNIK, novelty scoring, druggability, human-in-the-loop, Chemistry42, GENTRL, multi-objective reward functions, closed-loop learning, INS018_055

13.3.2 Case Study 2: Virtual Screening at Billion-Compound Scale

The section traces a billion-compound FADS1 screening campaign through a staged BioNeMo workflow and weighs its practical advantages against its evidence and limitations.

Key terms: FADS1, computational funnel, BioNeMo, ESM-2, ESMFold, protein embeddings, structural variants, MegaMolBART, molecular embeddings, known FADS1 modulators

13.3.3 Case Study 3: Protein Therapeutic Design - A Multi-Model Workflow

This section traces a constraint-aware, multi-model protein design workflow through a PETase example, then distinguishes computational designs from validated medicines.

Key terms: initial characterization, RoseTTAFold All Atom, functional motif, ESM-2, log-likelihood ratio, AlphaMissense, RFDiffusion, partial diffusion, backbone coordinates, conditioning

13.4 Clinical Translation: Hype vs. Reality

This section weighs AI drug discovery claims against early clinical results, distinguishing progress in molecular safety from unresolved efficacy and target-validation challenges.

Key terms: AI-discovered drugs, clinical trials, FDA approval, Phase 1, Phase 2, ADMET prediction, multi-objective optimization, target validation, AI-discovered targets, target prioritization

13.4.1 What AI Has Improved

This section identifies five improvements AI has made in drug discovery while distinguishing demonstrated discovery gains from unproven clinical benefits.

Key terms: discovery phase acceleration, computational screening, active learning, ADMET properties, computational prioritization, generative models, scaffolds, Tanimoto similarity, chemical space, data efficiency

13.4.2 What AI Has Not Solved

This section explains why faster AI-assisted discovery has not removed major clinical, biological, structural, safety, and manufacturing barriers to drug development.

Key terms: Phase 2, Phase 3, development timeline, target selection, target validation, multi-omics integration, knowledge graphs, patient heterogeneity, tissue context, disease progression

13.4.3 Current Limitations and Challenges

This section explains why data limitations, interpretability needs, and integration challenges make AI a co-pilot rather than an autopilot for drug discovery.

Key terms: ADMET, measurement noise, underrepresentation, training data, negative data gap, proprietary data silos, federated learning, black box, interpretability, linear models

13.4.4 Future Directions (2023-2030)

This section outlines three possible directions for AI-driven drug discovery—biological foundation models, AI virtual cells, and closed-loop laboratories—while distinguishing their potential from their present limitations.

Key terms: biological foundation models, unified representations, modalities, transfer knowledge, context-dependent relationships, emergent properties, unified models, AI virtual cells, digital twins, a priori knowledge

13.4.5 Final Comments

The section explains why end-to-end drug discovery needs integrated methods and how to assess claims about AI-driven results.

Key terms: protein sequences and structures, small molecule structures and properties, cellular phenotypes, clinical outcomes, platforms, simultaneous optimization, experimental testing, AI-discovered molecule, discovery phase acceleration, clinical trial timelines

13.5 Summary

Concepts explained in this chapter

← Chapter 12: Transformers for Protein Structure Prediction

These guides are generated from the text of Manning books by Manning's knowledge graph and link to the sections they draw on. The full books are available on liveBook and at manning.com.